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Breast cancer (BC) patients diagnosed between two screenings (interval cancers) are more
likely than screen-detected patients to carry rare deleterious mutations in cancer genes
potentially leading to increased risk for other non-breast cancer (non-BC) tumors. In this
study, we include 14,846 women diagnosed with BC of which 1,772 are interval and 13,074
screen-detected. Compared to women with screen-detected cancers, interval breast cancer
patients are more likely to have a non-BC tumor before (Odds ratio (OR): 1.43 [1.19–1.70],
P= 9.4 x 10−5) and after (OR: 1.28 [1.14–1.44], P= 4.70 x 10−5) breast cancer diagnosis, are
more likely to report a family history of non-BC tumors and have a lower genetic risk score
based on common variants for non-BC tumors. In conclusion, interval breast cancer is
associated with other tumors and common cancer variants are unlikely to be responsible for
this association. These findings could have implications for future screening and prevention
programs.
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Breast cancer screenings reduces breast cancer mortality byup to 35%1,2. However, in women regularly attendingscreening, between 20 and 30% of breast cancers are not
detected by screening mammography but are diagnosed between
screening intervals3. Failure of mammographic-screening proto-
cols to detect cancer can be attributed to many different factors
ranging from technical (e.g., imaging technology and radiologist
interpretation)4 to patient specific (e.g., age, co-morbidities, and
breast/mammographic density)5 to biological (e.g., the aggressive
tumor grows to pathological, and palpable size within the
screening window).
Compared with breast cancers detected at a screening, interval
cancers are characterized by more-aggressive tumor character-
istics and poorer prognosis (i.e., increased mortality) in most
recent studies (summarized in ref. 6). Patients with interval breast
cancer usually present with an average higher histological
grade7,8, larger tumor size9, and more-metastatic local lymph-
nodes10, a higher proportion of estrogen receptor (ER)8/proges-
terone receptor (PR) negativity11, a higher frequency of HER2
positivity8,9, and are more often triple negative12.
Currently, few risk factors for interval breast cancers are
known. Apart from high mammographic density13 and current
hormone replacement therapy (HRT)12,14 use, a previous false-
positive mammographic screening15 as well as family history of
breast cancer within first degree family members14–16 have been
implicated in interval cancer risk. Recently, we have shown that
interval cancer cases (compared with screen-detected cancers)
have a lower breast cancer genetic risk score (GRS), i.e., carry
fewer breast cancer risk increasing alleles17. Conversely, rare loss
of function mutations in 31 known and suspected breast cancer
predisposition genes were found to be more common in interval
cancer cases than in screen-detected cases18.
Loss of function mutations in those genes are also frequently
found to predispose individuals for other types of cancer19 and
may increase the incidence of other tumors in those individuals
or in close relatives. In this study, we find that interval cancer
patients are more likely than screen-detected patients to be
diagnosed with other tumors, either before or after breast cancer
diagnosis and that rather rare and not common variants are
responsible for the observed the association. Our results thus
reveal insights into risk and consequence of interval breast cancer.
Results
Investigating socio-economic and reproductive risk factors for
interval cancer. The current study included 14,846 breast cancer
patients (1,772 interval cancer patients and 13,074 screen-
detected cancer patients) from three cohorts (Table 1). Among
known breast cancer risk factors, we found that interval com-
pared with screen-detected breast cancer patients are more likely
to have given birth before 25 years of age (OR: 1.13, 95% CI:
1.00–1.27, PLR < 0.05, logistic regression, Wald test), are less likely
to have a college degree (OR: 0.85, 95% CI: 0.77–0.96, PLR < 0.01)
and are more likely to report the use of hormone replacement
therapy (OR: 1.29, 95% CI: 1.15–1.45, PLR < 0.001) as well as a
family history of breast cancer in close relatives (OR: 1.14, 95%
CI: 1.01–1.29, PLR < 0.05, Table 1). Importantly, interval cancers
were consistently more likely than screen-detected cancers to
have worse tumor characteristics and prognosis across the three
cohorts (Table 1 and Supplementary Fig. 1).
Prior and subsequent non-BC tumor diagnoses are associated
with interval cancer. We found that a prior non-BC tumor
diagnosis was highly significantly associated with increased risk
for interval compared with screen-detected cancer (OR: 1.43, 95%
CI: 1.19–1.70, PLR= 9.4 × 10−5, Fig. 1 and Table 1). Similarly,
interval cancer cases compared to screen-detected cases were at
higher risk to be affected with another non-BC tumor after breast
cancer (OR: 1.28, 95% CI: 1.14–1.44, PLR= 4.70 × 10−5, Fig. 1
and Table 1). Adjustment for age at first birth, education, BMI,
HRT as well as family history of breast cancer did virtually not
change the observed effect sizes and neither did the adjustment
for percent mammographic density (which was unavailable in
WHI) beyond the reduced sample size.
Next, we investigated which specific type of cancer diagnosis is
associated with interval breast cancer compared with screen-
detected breast cancer. We only investigated tumors which were
observed in at least 30 patients across the whole cohort and found
that a diagnosis of most cancer types is more common in interval
compared with screen-detected breast cancer (Fig. 1). We found
that a prior diagnosis of lung (OR: 2.57, 95% CI: 1.09–6.06, PLR <
0.05), colorectal (OR: 1.74, 95% CI: 1.02–2.97, PLR < 0.05) or skin
(OR: 1.70, 95% CI: 1.04–2.78, PLR < 0.05) cancer was significantly
associated with increased risk for interval breast cancer (Fig. 1).
The increased risk due to skin cancer can be attributed to both,
melanoma and non-melanoma skin cancers, although the
association was not statistically significant for the latter. Likewise,
compared with screen-detected breast cancer survivors, interval
cancer survivors are significantly more likely to be diagnosed with
colorectal cancer (OR: 1.48, 95% CI: 1.00–2.18, PLR < 0.05) as well
as skin (OR: 1.48, 95% CI: 1.04–2.11, PLR < 0.05) cancer.
However, here, the observed association of skin cancer with
interval cancer risk was mostly restricted to non-melanoma skin
cancers.
Genetic insights into the association of interval breast cancer
with non-BC tumors. In order to elucidate potential genetic
causes for the observed increased non-BC tumor prevalence in
interval breast cancer patients, we investigated whether interval
cancer patients are more likely to report a family history of other
cancers compared with screen-detected patients. When we
restricted the analyses to those individuals with any non-BC
tumor diagnosis, we found that interval breast cancer patients
compared with screen-detected patients are almost twice as likely
to report a family history of non-BC tumors (OR: 1.94, 95% CI:
1.00–3.68, PLR < 0.05, Table 2). This association was more pro-
nounced in patients with a prior non-BC tumor diagnosis (OR:
3.41, 95% CI: 1.28–9.14, PLR < 0.01) than in patients that were
diagnosed with a tumor diagnosis after breast cancer (OR: 1.48,
95% CI: 0.89–3.52, PLR > 0.05).
The increased prevalence of non-BC tumor diagnoses in
interval compared with screen-detected breast cancers can
potentially be attributed to common genetic risk factors. In line
with prior studies20, we found that interval cancer patients
compared with screen-detected patients have a significantly lower
breast cancer genetic risk score in the combined study (OR per
standard deviation (SD): 0.85, 95% CI: 0.76–0.95, PLR < 0.01,
Fig. 2). Next, we computed 12 genetic risk scores for different
cancers (Fig. 1) from a total of 304 genome-wide significant
cancer risk increasing variants and an all non-BC tumor genetic
risk score by calculating the sum of the individual cancer scores.
We excluded all variations in published, genome-wide significant
breast cancer loci in order to exclude potential pleiotropic effects
of known BC variants on other cancers (Supplementary Data 1
and Supplementary Fig. 2). As expected, all of the cancer-specific
genetic risk scores were not positively correlated to the breast
cancer score, indicating that they likely capture common cancer
genetics independent of known BC genetic variance (Supple-
mentary Fig. 2). Similar to the breast cancer genetic score, we
found that interval breast cancer cases had a significantly lower
number of non-BC tumor risk increasing alleles (OR per SD of
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the all non-BC tumor genetic risk score: 0.88, 95% CI: 0.80–0.96,
PLR < 0.01, Fig. 2) compared with screen-detected patients. We
also investigated if this effect can be attributed to any cancer-
specific genetic score (Fig. 2) and found that the genetic risk score
for skin cancer was significantly associated with reduced risk for
interval breast cancer compared with screen-detected breast
cancer (OR per SD: 0.91, 95% CI: 0.83–0.99, PLR < 0.05). Similar
to the results observed from the actual tumor diagnoses, we found
that the risk score for non-melanoma skin cancer was more
strongly associated with reduced disease risk than the melanoma-
specific risk score. Importantly, most of the other genetic risk
scores are also protective for interval compared with screen-
detected cancer.
Finally, we investigated the association of individual cancer risk
variants with interval breast cancer risk (Supplementary Data 1).
Although several variants were nominally significantly associated
with interval breast cancer (PLR < 0.05), after adjustment for
multiple testing (Bonferroni correction), none of the variants
remains statistically significantly associated.
Discussion
In this study, we showed that non-BC tumors, either before or
after BC diagnosis, are associated with interval breast cancers and
that in breast cancer patients with a second primary tumor
diagnosis, interval compared with screen-detected patients are
three times more likely to report a family history of other cancers.
In addition, we demonstrated that interval cancer patients com-
pared with screen-detected patients have fewer common cancer
risk increasing alleles of both, breast cancer, and other cancers.
Our results are in line with recent findings that interval breast
cancer patients compared with screen-detected patients have
fewer common breast cancer risk increasing alleles and, on the
other hand, are more likely to carry rare deleterious (loss of
function) mutations in known or suspected cancer genes17,18.
Although previous efforts to identify cancer genes have largely
focused on single tumor types, recent evidence suggests a pleio-
tropic role those genes21 owing to their involvement in funda-
mental processes required for tumor initiation and propagation
such as genomic integrity22,23, hormonal processes, angiogenesis,
and inflammation24. As such, mutations in those genes frequently
predispose for different cancers and cancer syndromes21,25 and
might result in multiple tumor diagnoses over an individual’s
lifetime as well as increase familial risk for tumors. Importantly,
patients with germline mutations in cancer genes are often
diagnosed with more-aggressive and fast growing tumors26–28
and thus may more likely be diagnosed with interval than screen-
detected breast cancer. Nevertheless, mutations in currently
known cancer genes can only explain a small portion of the
observed association. Thus, further large-scale sequencing efforts
in patients with multiple tumors are necessary to uncover the
genetic basis for both, multiple cancer diagnoses and increased
interval breast cancer risk.
In addition to the overall increased occurrence of other cancers
in interval compared with screen-detected breast cancer patients,
we found that virtually all types of cancer are more common in
interval compared with screen-detected cancer patients. Although
we only found a statistically significant increase of prior lung,
skin, and colorectal as well as subsequent skin and colorectal
tumors in interval compared with screen-detected cases, the lack
of significance for the other cancers can be mainly attributed to
the limited number of interval breast cancer patients with other
tumor diagnoses in our data set. Interestingly, we did not find an
increased number of ovarian cancer survivors in interval com-
pared with screen-detected breast cancer patients, although both,
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risk factors29,30. However, those genetic factors only explain a
fraction of the breast cancer cases in ovarian cancer survivors31.
Therefore, in order to find such an association, we would have to
restrict our analysis to younger cases with multiple cancer diag-
noses in their family, which is not possible owing to limited
number of individuals that survived ovarian cancer in our data
set. Alternatively, removal of both the uterus and the ovaries/
fallopian tubes as part of ovarian cancer treatment may change
sex hormone levels favorably for interval cancer risk, which is
likely linked to hormonal changes owing to its risk association
with hormone replacement therapy. The increased number of
non-BC tumors in interval cancer cases compared with screen-
detected cases can potentially be influenced by several factors. For
instance, more-aggressive treatment of interval cancer
patients32,33 could result in increased tumor incidence. However,
as noted above, we found an increased occurrence of almost all
particular cancers, thus, disqualifying treatment effects from
being a major influence on the association34,35.
Rare mutations that are associated with a strong increase in
risk and a worse prognosis in breast cancer are more frequent in
interval cancer patients than in screen-detected patients18 and
are also often aggregated in families with a (breast) cancer
history. Accordingly, we found that family history of non-BC
tumors is associated with increased risk for interval compared
with screen-detected cancer (and consequently with worse
prognosis) in patients with another tumor diagnosis. Impor-
tantly, the association of family history of non-BC tumors with
increased interval cancer risk was found in patients with either
a prior or a subsequent tumor. The association of non-BC
family history with interval cancer was markedly stronger in
patients with a prior compared with a subsequent non-BC
tumor diagnosis. The reduced effect size can potentially be
attributed to the increased incidence of secondary non-BC
tumors that arise by chance with advanced age and are not
linked to a strong rare genetic predisposition but rather shared
environmental or behavioral factors, diluting the observed
association36,37.
The finding that both, common breast cancer and non-BC risk
increasing alleles, are less frequent in interval compared with
screen-detected cancer provides insights into the genetic basis of
interval breast cancer. A possible explanation for common breast
cancer alleles being associated with screen-detected (less aggres-
sive) tumors may be attributed to the study population in which
the common variants were identified. Most breast cancer patient
Any cancer Any cancer
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Fig. 1 Prior and subsequent non-BC tumor diagnoses in IC compared with SDC. The effect size estimates of the association with interval breast cancer (IC)
risk (black squares) compared with screen-detected breast cancer (SDC) as well as the 95% confidence intervals (CI, horizontal lines) for different prior
and subsequent cancers are shown. The exact estimates derived from logistic regression models adjusted for age at diagnosis are given on the right-hand
side of the plot with the accompanying 95% CI. a A prior non-BC tumor diagnosis (any type) as well as a prior lung, skin, non-melanoma skin, or colorectal
cancer diagnosis was significantly associated with increased risk for IC compared with SDC. b A non-BC tumor diagnosis after breast cancer (any type)
as well as a subsequent colorectal, skin, or non-melanoma skin cancer diagnosis was significantly more common in IC cases than in SDC cases. *P < 0.05;
**P < 0.01; ***P < 0.001
Table 2 Association of non-BC family history with interval breast cancer
Other cancer statusa Family history in IC patients (%) (N)b Family history in SDC patients (%) (N)b OR (95% CI)c
All patients 14.10 (454) 15.53 (2280) 0.935 (0.691, 1.249)
Any non-BC tumor 24.05 (79) 16.26 (289) 1.935 (1.001, 3.675)*
Any prior non-BC tumor 37.93 (29) 16.04 (106) 3.411 (1.284, 9.140)**
Any non-BC tumor after BC 17.31 (52) 15.71 (191) 1.484 (0.589, 3.523)
a Stratification of patients according to non-BC tumor status
b Family history of tumors other than breast cancer was only available in WHI and KARMA
c Odds ratio and 95% confidence intervals (in brackets) of the assocation of non-BC tumor family history with interval breast cancer compared with screen-detected cancer in Caucasians. The logistic
regression models were adjusted for age at diagnosis, study and the all non-BC cancer GRS
IC interval breast cancer, SDC screen-detected breast cancer, *P < 0.05; **P < 0.01, N number of individuals with non-missing family history information
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cohorts are likely enriched for screen-detected cancers and breast
cancer survivors. In addition, most of the patients in the cohorts
which are part of the Breast Cancer Association Consortium
(BCAC)38 have ER-positive tumors and thus, a large proportion
of the previously reported common variants may show a stronger
association with ER-positive breast cancers, which are in turn
associated with more benign tumors compared with ER-negative
breast cancers. In addition, those genome-wide association stu-
dies were not designed to identify interval cancer-specific variants
and thus the aggregate score would not be expected to reflect such
an association. However, here, we show that other cancer risk
increasing alleles are also less frequent in interval compared with
screen-detected cancer patients, implicating that common cancer
risk increasing alleles, in general, result less aggressive (screen-
detected) breast cancer. Similar to the notion that the BCAC
cohorts are more likely to include less-aggressive breast cancer
cases, large case–control cohorts for other cancers may also be
enriched for cancer survivors with less severe phenotypes.
Therefore, genetic risk scores based on those association results
may also predict milder phenotypes and more favorable prog-
nosis. Alternatively, although we excluded variants in known BC
loci in order to reduce the influence of known BC risk variation in
the current analysis, it is possible that there is pleiotropy with BC
present in the other cancer genetic risk scores, which is not
captured by known BC risk variants and could potentially drive
the association.
In order to expand the number of available studies with
interval breast cancer status, this, to our knowledge, is the first
study to compute incident interval breast cancer status from
questionnaire in the Women’s Health Study. Although the precise
screening history and mammographic density estimates were not
available in the WHI, compared with both Swedish studies, we
observed that the interval cancer cases derived from questionnaire
data have a comparable risk factor and tumor characteristic dis-
tribution as well as a similar prognosis. The effect sizes were,
however, generally weaker in the Women’s Health Initiative
(WHI) than in the Swedish cohorts and several factors may
explain this observation. First, misclassification of interval cancers
in the WHI is possible because we computed incident interval
breast cancer status from questionnaire rather than using precise
screening history. Second, the WHI did not report density mea-
surements, thus preventing us from excluding intervals cancers
missed at screening owing to masking effects of high mammo-
graphic density. Third, the increased age of the WHI participants
may have resulted in increased mortality and thus lower inci-
dence of other tumors after breast cancer diagnosis. However,
these limitations are likely to dilute rather than inflate the
observed results, as restricting our main analysis to individuals
from LIBRO-1 and KARolinska MAmmography project for risk
prediction of breast cancer (KARMA) (i.e., studies which have
actual prior screening dates) yielded consistent results (Supple-
mentary Fig. 3).
The current studies aimed at providing insights into interval
cancer (genetics) in order to further characterize tumors devel-
oping in women not currently benefiting from regular mammo-
graphic screenings. Thus, the current results are not intended to
be directly relevant for clinical practice beyond raising awareness
that some of these patients and family members are at increased
risk for interval breast cancer and other tumors. Although the
increased risk for interval cancer in cancer survivors may have
potential implications for screening or prevention programs,
other risk factors, co-morbidities as well as their potential impact
Breast cancer GRS































Fig. 2 Cancer genetic risk scores in interval breast cancer risk. Cancer genetic risk scores (GRS) were computed in Caucasian patients from the LIBRO-1
(N= 1784), KARMA (N= 1690) and WHI (N= 1585) studies. The odds ratios of different cancer genetic risk scores (GRS) on interval breast cancer (IC)
risk (black squares) compared with SDC as well as the 95% confidence intervals (CI, horizontal lines) were computed with logistic regression, adjusted for
age at diagnosis, study and the first three principal components. The exact estimates are given on the right-hand side of the plot with the accompanying
95% CI. The breast cancer GRS, skin cancer GRS, non-melanoma skin cancer GRS as well as the combined all cancer GRS computed from the cancer risk
increasing alleles of 304 variants (excluding any variants in known BC loci) was statistically significantly associated with a protective effect on IC risk
compared with SDC. The other cancer-specific GRS were not significantly associated, although the majority of scores had a protective effect on IC. The
GRS effect sizes are given per standard deviation of the score. *P < 0.05; **P < 0.01
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on prognosis need to be considered jointly in disease
management.
One of the limitations of our current study is that the types of
tumor reported in close family members (i.e., family history of
other cancers) in KARMA and WHI differed. In KARMA, par-
ticipants were asked about ovarian and pancreatic cancer in close
relatives while in WHI any type of cancer in close family mem-
bers was ascertained. Furthermore, the variable was missing from
the LIBRO-1 study. In addition, the frequency of estrogen
receptor-positive tumors is somewhat higher in our IC cases
compared with the frequencies observed in IC patients from other
studies39–41, which can be attributed to different periods of
inclusion and differences in recruitment strategy. However, those
differences should not affect the main conclusions of this study.
Finally, in this study we have not identified the actual cause of the
increased frequency of other tumors in interval compared with
screen-detected patients and thus were only able to speculate on
potential mechanisms. Among the strengths of this study are its
large sample size with a broad range of available risk factor,
tumor characteristics, and mortality data, precise ascertainment
of other cancers before and after BC diagnosis, the inclusion of
breast cancer patients from different study designs (population
based and prospective study) as well as the inclusion of both, pre-
and post-menopausal women.
In conclusion, we show that either a previous or a subsequent
non-BC tumor diagnosis was more common in interval com-
pared with screen-detected breast cancer in three independent
cohorts and that common cancer risk increasing variants are
unlikely to be responsible for this association. The association of
family history of other cancers with interval cancer risk suggests
that rare penetrant cancer mutations predispose individuals for
both, interval breast cancer and other cancers and further large-
scale sequencing efforts (especially in patients with more than one
tumor) are necessary to uncover the underlying cause of the
observed associations. Our results thus reveal insights into risk
and consequence of interval breast cancer and highlight further
genetic differences between interval and screen-detected breast
cancer, which could have significant implications for future
screening programs and the clinical management of cancer
survivors.
Methods
Study population. Ethical approvals of the KARMA and LIBRO-1 studies were
given by the ethical review board at Karolinska Institutet (Stockholm, Sweden) and
written informed consent was obtained from all participants. Study approval for
data analysis in the Women’s Health Initiative (WHI, ClinicalTrials.gov Identifier:
NCT00000611) was granted by the Regional Ethical Review Board in Stockholm,
Sweden. Data from the WHI were retrieved from the Database of Genotypes and
Phenotypes (dbGAP, URL: https://www.ncbi.nlm.nih.gov/gap) under the accession
number phs000200.v11.p3, with approval from the data-access committee.
KARMA is a mammography screening-based study initiated in January 2011
and includes women who attended mammography screening or clinical
mammography at four hospitals in Sweden42,43. As the date of breast cancer
diagnosis, we only counted the first occurrence of breast cancer. Breast cancer risk
factors (such as family history of breast cancer and other cancers, body mass index,
smoking status, and hormone replacement therapy at diagnosis), socio-economic
factors as well as reproductive events were ascertained from mailed questionnaire.
In addition, tumor characteristics were retrieved from the Swedish cancer registry
and survival after breast cancer was ascertained from the Swedish causes of death
registry, as described before43 with virtually no missing data.
LIBRO-1 is a breast cancer cohort with 5715 patients who gave informed
consent and were diagnosed between 2001 and 2008 in the Stockholm/Gotland
area. Similar to the KARMA study, breast cancer risk factors, socio-economic
factors, and reproductive events were assessed by questionnaire and tumor
characteristics as well as cause and date of death were retrieved from the respective
Swedish registries. However, family history of tumors other than breast cancer was
not available in LIBRO-1.
In order to expand the number of patients for our analysis and to investigate
our findings in a large collection of incident breast cancer patients, we included
breast cancer patients from the Women’s Health Initiative. The WHI is a
prospective national health study of >160,000 post-menopausal women aged 50–79
recruited between 1993 and 1998 at 40 clinical sites in the United States44,45, with
an average follow-up time of 17.20 (S.D. 4.17) years.
The study consists of two major parts: (1) the observational study without
intervention, and (2) the clinical trial arm which investigated the role of hormone
replacement therapy, dietary modification, and vitamin supplementation on
different outcomes such as cancer, cardiovascular disease, and osteoporosis. We
identified 11,031 women with incident BC, whose BC status was ascertained by
medical review (and excluded BC cases that were ascertained by death certificate).
All demographic and socio-economic variables, breast cancer risk factors, and
tumor characteristics were extracted from the respective aggregate outcome or
questionnaire tables as deposited in dbGAP. The breast cancer patients in the WHI
were comprised of different ethnicities: 87.7% were self-reported Caucasians, 6.8%
were Blacks or African-Americans, 2.0% were Asians and 2.2% were Hispanics/
Latinos, whereas 0.9% reported to belong to another ethnic group. We did not
observe significant a difference in interval cancer incidence between ethnicities and
thus analyzed all BC cases in WHI jointly while adjusting the statistical analyses for
self-reported ethnicity.
Interval cancer ascertainment. In both, the KARMA and LIBRO-1 study, interval
cancer status was ascertained as recently described12,46. In brief, all women in the
Stockholm area aged 50–69 have been invited to participate in regular mammo-
graphic screenings every 24 months since 1989, whereas women aged 40–49 were
included from mid-2005 and screened at 18-month intervals. A BC diagnosed after
a negative mammographic screening before the next scheduled screening visit was
considered interval breast cancer. Conversely, cancers diagnosed at a regularly
scheduled mammographic screening were deemed screen-detected cancer. Patients
who did not attend the screening mammogram prior to breast cancer diagnosis
(i.e., their last screening mammogram was >18/24 months before breast cancer
diagnosis) or with missing prior screening information were excluded from our
data sets. We also determined the mammographic density of the prior screening
mammogram (i.e., the last mammogram preceding breast cancer diagnosis) with
STRATUS, a machine-learning algorithm capable of computing density from both,
analog and digital mammograms47. Patients without data on mammographic
density (e.g., owing to missing mammographic images) were excluded from the
KARMA and LIBRO-1 study. Furthermore, we also excluded interval cancer
patients (but not screen-detected patients) with medium or high mammographic
density (percent mammographic density > 25), as the tumor might have been
masked by the high dense tissue and thus not been detected at the prior screening
mammogram. Accordingly, this collection of interval breast cancer cases should
represent ‘true’ interval cancer cases not confounded by missed screen-detected
tumors.
In KARMA, out of 3862 BC patients, we excluded 287 patients who did not
attend their scheduled screening mammogram prior to the BC diagnosis, 680
patients with no history of screening prior to BC diagnosis and 216 patients with
missing mammographic density estimates. We also excluded 427 out of 822 (52%)
interval cancer patients with medium or high mammographic density. In total,
2252 BC patients (either interval cancer cases or screen-detected cases) were
included in the present study (Table 1). Similarly, in LIBRO-1, we excluded 1014
patients which did not attend their last screening, 1800 patients, which never
attended screening before breast cancer or were diagnosed before their first
invitation, 562 patients with missing mammographic density information as well as
417 out of 641 (65%) interval cancer cases with medium or high dense breasts
(percent mammographic density > 25). In total, 1922 women with either interval or
screen-detected BC were included in the present study (Table 1).
In the WHI, interval cancer status was determined from the self-reported
mammography questionnaire data ascertained annually by mail or interview. In
case a woman reported a mammographic screening since the last follow-up, we
assumed that the mammogram was taken in the middle of this interval (i.e.,
between the present and the previous follow-up questionnaire) and compared
those screening dates with the date of breast cancer diagnosis. In order to account
for imprecision in determining the accurate screening date, we defined a breast
cancer diagnosed within 3 months of an estimated screening date as screen-
detected cancer, whereas breast cancers diagnosed between three and 24 months
after the last screening were considered interval cancers. We also excluded patients
without information on their mammographic screening history (N= 370) as well
as those who did not report attending a mammographic screening more than 2
years prior to breast cancer diagnosis. (N= 259). In total, 10,672 post-menopausal
breast cancer patients from both, the observational and clinical trial arms were
included in the current study (Table 1).
Utilizing our approach, we found that there were 87.26 breast cancer diagnoses
(8.9 interval and 73.49 screen-detected) per 10,000 self-reported mammographic
screens, in line with numbers typically observed in screened populations6. The
average time between reported screenings was 581.69 days (S.D. 350.10), in line
with a mixture of women screened annually and biennially. The average time
between prior mammogram and interval cancer diagnosis was 243.89 days (S.D.
163.32). Thus, 82% of the identified interval cancer cases were discovered within
one year after the last screening in WHI compared with 42 and 33% in KARMA
and LIBRO-1, respectively. However, previous research has shown that there is
little difference in tumor characteristics between interval breast tumors detected
within the first or second year of the screening regimes6,12. In general, the women
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in the WHI were diligent in answering their yearly questionnaire with an average
time between yearly questionnaires of 383.92 days (S.D. 77.03)
Assessment of non-BC tumor diagnosis. For both, KARMA and LIBRO-1
participants, extensive registry data are available. Thus, for breast cancer patients in
those studies, we extracted the number of (prior and subsequent) non-BC tumor
diagnoses from the Swedish cancer registry. We only counted (solid) cancer
diagnoses within 15 years prior to breast cancer diagnosis and available ICD10
code. We did not include women diagnosed with prior non-BC tumor diagnoses
less than 1.5 years (540 days) before breast cancer diagnosis, as the breast cancer
might be diagnosed in the diagnostic workup of the previous cancer48 and thus be
incorrectly detected as interval cancer. In addition, we calculated the occurrence of
specific (common) cancers in women: lung (ICD10 code: C34), cervical (C53),
endometrial (C54), colorectal (C18 and C20), skin (C43 and C44), non-melanoma
skin cancer (C44), melanoma (C43), ovarian (C56), thyroid (C73), central nervous
system (C69–72), pancreas (C25), bladder (C67), or kidney cancer (C64).
All 10,672 post-menopausal BC patients in WHI were incident breast cancer
cases and we counted the number of (centrally adjucated/evaluated) other, solid
non-BC tumor diagnoses between study enrollment and the first breast cancer
diagnosis and those that occurred after the first BC diagnosis. In the WHI, only
melanoma diagnoses were available and thus skin cancer only included melanoma
cases and no non-melanoma skin cancers. Similarly, we documented the diagnosis
of the same specific tumors as above and did not consider women with non-BC
tumor diagnoses that occurred within 1.5 years before BC diagnosis.
Genotyping and imputation. Patients in KARMA and LIBRO-1 were genotyped
through the BCAC on a custom Ilumina iSelect genotyping array as part of the
Collaborative Oncological Gene-environment Study (iCOGS) or on the OncoAr-
ray. The genotyping data used for this study from the KARMA project was first
described in ref. 38 for 398 individuals genotyped on the iCOGS array and in ref. 49
for 1292 women genotyped on the OncoArray platform. Similarly, 1784 women in
LIBRO-1 (as part of the pKARMA study) were genotyped on the iCOGS array
which was first described in ref. 38. Quality control and imputation of missing and
un-genotyped variants was performed by the BCAC. In brief, missing genotypes
were imputed to the 1000 Genomes Phase 3 reference haplotypes using ShapeIt50
and IMPUTE51 and variants with an imputation quality (R2) > 0.8 and a minor
allele frequency > 0.01 were retained.
Patients from the WHI were genotyped on different genotyping platforms as part
of various sub-studies and were jointly imputed to the 1000 Genomes Phase 3
reference by the WHI investigators. Imputed genotype data were retrieved from
dbGAP (accession: phs000746) for 971 out of 9103 self-identified Caucasian BC
cases52 in the minimac53 dosage/matrix format and converted to variant call format
(vcf) in R54. The genotypes were coded as the expected genotype dosage (DS) of each
non-reference (ALT) allele. We excluded variants that were poorly imputed (R2 <
0.3) or which showed a significant deviation from Hardy–Weinberg–Equilibrium
(HWE, P < 1.00 × 10−6, HWE exact test). We also extracted the un-imputed
genotypes of an additional 614 BC cases genotyped on the Metabochip as part of the
PAGE WHI study55 (accession: phs000227) and imputed missing genotypes using
the 1000 Genomes Phase 3 (version 5) reference haplotypes. First, we excluded very
rare and poorly performing genotyped variants (deviation from HWE (P < 0.0001,
HWE exact test), minor allele frequency < 0.001, missing rate per variant > 30%) and
poorly genotyped samples (missing rate overall >5%). Next, the phase of each variant
was determined with ShapeIt251 and missing genotypes were imputed with
minimac356 with standard settings. We excluded poorly imputed variants with the
same criteria as above. Finally, we merged all imputed genotype sets with bcftools57
to generate a single genotype file for all genotyped samples.
In order to account for potential population stratification and mixed ethnicities,
we computed the first three principal components from the relatedness matrix
derived from imputed genotypes with QCTOOL (http://www.well.ox.ac.uk/~gav/
qctool) for all studies.
Genetic risk scores calculation. We calculated the genetic risk score as the effect
size (log odds ratio) weighted sum of cancer risk increasing alleles, normalized to
the average effect size of all variants17,58,59. Thus, an increase in one point of the
genetic risk score corresponds to having one additional risk allele with average
effect size. For the BC genetic risk score, we included 158 variants associated with
breast cancer risk with genome-wide significance (P < 5.00 × 10−8), as recently
reported by BCAC (Supplementary Data 1)60.
In addition, we computed genetic risk scores for 12 different, common cancers
from genome-wide significant variants (identified primarily in Caucasian/European
populations) retrieved from the GWAS catalog61 (version 1.0.2, accession date: 25
June, 2018, Supplementary Data 1). We excluded variants that are located in
known, genome-wide significant breast cancer loci60. A known breast cancer locus
was defined by the most distant variants in moderate linkage disequilibrium (R2 >
0.5) with the genome-wide significant lead variant and an additional 500,000 base-
pairs added up- and downstream. In particular, we computed a non-BC genetic
risk score for colorectal cancer (35 variants), endometrial cancer (5 variants), lung
cancer (78 variants), skin cancer (57 variants), melanoma (18 variants), non-
melanoma skin cancer (39), ovarian cancer (29 variants), bladder cancer (11
variants), thyroid cancer (11 variants), central nervous systems (36 variants), renal
cancer (15 variants), and pancreatic cancer (14 variants). We did not compute a
genetic score for cervical cancer as there were less than five genome-wide
significant variants in Europeans reported as of 25 June, 2018. For the all non-BC
cancer genetic risk score, we computed the sum of the individual genetic risk
scores, effectively generating a compound score of 304 variants associated with 12
different cancers, excluding variations in known breast cancer susceptibility loci
(see Supplementary Data 1).
Statistical analyses. All statistical analyses were performed in R54. We used
logistic regression, adjusted for age at diagnosis to identify factors that were sig-
nificantly different between screen-detected and interval cancers. In addition, in the
joint/pooled analyses, we additionally adjusted for study. The reported P values of
association from the logistic regression models were based on a Wald test and are
denoted as PLR. All genetic analyses were restricted to individuals from European
descent (Caucasians) and additionally adjusted for the first three principal com-
ponents of ancestry computed from the imputed genotypes.
In order to estimate the effect of interval cancer diagnosis on overall (all cause)
and/or breast cancer-specific survival, we fit Cox proportional hazard models
(adjusted for age at diagnosis) as implemented in the survival package62. We
plotted the results with the ggadjustedcurves function (from the package
survminer63 implemented in R).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Genotypes and phenotypes from the Women’s Health Initiative is available through
dbGAP (accession phs000200.v11.p3). Access to phenotypes, biospecimen and genotypes
from the KARMA study can be requested from https://karmastudy.org/data-access/.
Access to the LIBRO-1 phenotypes and genotypes is restricted due to IRB requirements
but data can be shared upon reasonable request to the PIs of LIBRO-1 (Kamila Czene
and Per Hall).
Code availability
The analysis script to compute risk factors, tumor characteristics as well as interval
cancer status in the WHI based on the phenotypic information and questionnaire data
retrieved from dbGAP is available at https://github.com/GrassmannLab/IC_WHI.
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